Aurobindo Pharma and US-based Covaxx have entered into a license agreement to develop, commercialise and manufacture a vaccine to fight Covid-19 for India and the United Nations Children's Fund (UNICEF) agency.
Covaxx is currently conducting a phase one clinical trial for the vaccine candidate UB-61.
"We are proud to partner with Covaxx in developing the first-ever synthetic peptide-based vaccine to combat the Covid-19 pandemic," said N Govindarajan, Managing Director of Aurobindo Pharma.
"This vaccine has immense potential in eliminating shedding and hence containing the spread of pandemic," he said in a statement on Thursday.
Aurobindo has the capacity of manufacturing 220 million doses in multi-dose presentation and is building additional facilities to have a total capacity of nearly 480 million doses by June next year.
Under the signed agreement, Aurobindo has obtained exclusive rights to develop, manufacture and sell Covaxx's UB-612 vaccine in India and to UNICEF as well as non-exclusive rights in other select emerging and developing markets.
( With inputs from ANI )
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor